Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Travoprost 0.004%/timolol 0.5% fixed combination.

Robert J Noecker1, Nida S Awadallah, Malik Y Kahook

  • 1UPMC Eye Center, Eye and Ear Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA. noeckerrj@upmc.edu

Drugs of Today (Barcelona, Spain : 1998)
|March 14, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective Pilot Study of Sustained Release Bimatoprost Implant with SpyGlass Intraocular Lens: 3-Year Results.

Ophthalmology and therapy·2026
Same author

Histopathological Changes After Standard and Novel Endoscopic Cyclophotocoagulation versus Transscleral Cyclophotocoagulation in Human Cadaveric Eyes.

Clinical ophthalmology (Auckland, N.Z.)·2025
Same author

A Systematic Review of the PAUL Glaucoma Implant.

Clinical ophthalmology (Auckland, N.Z.)·2025
Same author

One year clinical outcomes with a novel canaloplasty device in mild to severe open angle glaucoma.

International journal of ophthalmology·2025
Same author

Acute Structural Effects of Novel Endoscopic Cyclophotocoagulation versus Standard Endoscopic and Transscleral Cyclophotocoagulation.

Clinical ophthalmology (Auckland, N.Z.)·2025
Same author

ChatGPT Assisting Diagnosis of Neuro-Ophthalmology Diseases Based on Case Reports.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society·2025

Fixed-combination travoprost/timolol eye drops effectively treat open-angle glaucoma and ocular hypertension. This combination improves patient adherence and may reduce healthcare costs.

Area of Science:

  • Ophthalmology
  • Pharmacology

Background:

  • Open-angle glaucoma and ocular hypertension are common conditions requiring intraocular pressure (IOP) lowering therapy.
  • Current treatments involve multiple topical agents, which can impact patient adherence and healthcare costs.

Purpose of the Study:

  • To review the efficacy and safety of fixed-combination travoprost/timolol eye drops.
  • To evaluate the benefits of fixed-dose combination therapy for IOP management.

Main Methods:

  • Literature review of clinical trials comparing fixed-combination travoprost/timolol to other treatment regimens.
  • Analysis of studies assessing patient adherence and cost-effectiveness.

Main Results:

  • Fixed-combination travoprost/timolol (0.004%/0.5%) is effective and safe for once-daily use.

Related Experiment Videos

  • Demonstrated non-inferiority or superiority compared to concomitant therapies and monotherapy in various studies.
  • Potential to improve patient adherence and reduce overall treatment costs.

    • Conclusions:

    • Fixed-combination travoprost/timolol offers a valuable therapeutic option for managing open-angle glaucoma and ocular hypertension.
    • Simplifying treatment regimens with fixed-dose combinations can enhance patient adherence and potentially lower healthcare expenditures.